ReviewFrontiers in oncology2018
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Adoptive cell therapies in thoracic malignancies: a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.EMBO molecular medicine · 2024Article
- CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.Nature communications · 2024Article
- Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.Cellular & molecular immunology · 2024Review
- Review
- CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.Cancer gene therapy · 2023Article
- Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.Cellular and molecular life sciences : CMLS · 2022Article
- Latest developments in the pathobiology of Ewing sarcoma.Journal of bone oncology · 2022Review
- CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology · 2022Article
- Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.Journal for immunotherapy of cancer · 2022Article
- Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity.Cells · 2021Review
- Review
- Surface expression of the immunotherapeutic target GCancer reports (Hoboken, N.J.) · 2021Article
- The Role of Sphingolipids in Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.Frontiers in immunology · 2021Review
- The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.Japanese journal of clinical oncology · 2020Review
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.Cancer cell · 2020Review
- Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Application of the CAR targeting strategy in solid tumors is challenged by the need for adequate target antigens. As a consequence of their tissue origin, embryonal cancers can aberrantly express membrane-anchored gangliosides. These are carbohydrate molecules consisting of a glycosphingolipid linked to sialic acids residues. The best-known example is the abundant expression of ganglioside G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.